Welcome to our dedicated page for CRISPR Therapeutics SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR Therapeutics AG filings document operating results, pipeline disclosures and capital-structure matters for a Swiss biopharmaceutical company developing gene-based medicines. Form 8-K reports furnish quarterly and annual financial results, business highlights for CASGEVY and investigational programs, clinical and regulatory updates across cardiovascular, autoimmune, immuno-oncology and regenerative medicine, and material-event disclosures.
The filing record also includes proxy materials covering shareholder voting and executive compensation, shelf-registration and prospectus-supplement disclosures for common-share offerings, and material definitive agreements for convertible senior notes due 2031. These filings describe common shares, equity financing mechanics, debt terms, governance matters and business disclosures tied to the company’s CRISPR/Cas9, LNP, CAR-T and siRNA platforms.
CRISPR Therapeutics (CRSP) insider activity: The company’s Chief Executive Officer and Director reported the vesting of 8,334 restricted stock units on 10/13/2025, increasing direct holdings. On 10/14/2025, 4,242 common shares were sold at $66.6 to satisfy tax withholding mandated by the company’s RSU Settlement Policy.
Following these transactions, directly held common shares were 205,096, with an additional 85,662 held indirectly via The Kulkarni 2023 GRAT. The RSU grant was part of a 25,000‑share award vesting in three annual tranches.
CRISPR Therapeutics AG filed a prospectus supplement to offer and sell, from time to time and at its sole discretion through Jefferies as sales agent, additional common shares with an aggregate offering price of $600,000,000. The common shares will be issued under the company’s automatically effective shelf registration statement on Form S-3ASR (File No. 333-281262) filed on August 5, 2024.
The filing notes the engagement of Jefferies LLC under an existing Open Market Sale Agreement and includes a legal opinion from Walder Wyss AG as Exhibit 5.1. This action provides the company with the ability to raise capital over time via open market sales, subject to applicable securities laws.
CRISPR Therapeutics AG launched an at‑the‑market offering of up to $600,000,000 of common shares, to be sold from time to time through Jefferies as sales agent under an existing Sales Agreement. Sales may be made in transactions deemed an “at the market offering” under Rule 415(a)(4). Jefferies will use commercially reasonable efforts and earn a commission of up to 3.0% of the gross sales price; there is no escrow arrangement.
The company expects to use potential net proceeds to fund research and clinical development, platform extensions, manufacturing infrastructure, working capital and general corporate purposes. Estimated offering expenses are approximately $6.4 million, which include a Swiss federal securities issuance stamp tax of 1%.
The prospectus provides an illustrative dilution scenario assuming sales at $68.29 per share, showing immediate dilution of $44.76 per share to new investors. Common shares outstanding were 88,376,439 as of June 30, 2025.
CRISPR Therapeutics (CRSP) reported an insider equity award. The Chief Executive Officer and Director received a stock option covering 49,500 Common Shares on October 3, 2025 with an exercise price of $67.74 per share. The option vests in 48 equal monthly installments, beginning November 3, 2025, and expires on October 3, 2035. The filing lists the holding as Direct ownership.
CRISPR Therapeutics AG (CRSP) reported an insider equity award. The company’s Chief Medical Officer received a stock option covering 16,500 common shares with an exercise price of $67.74 on October 3, 2025. The option expires on October 3, 2035.
The award vests in 48 equal monthly installments, beginning November 3, 2025. Following the grant, 16,500 derivative securities were beneficially owned, shown as Direct (D) ownership.
CRISPR Therapeutics AG reported an insider transaction on Form 4 for its Chief Financial Officer. The filing discloses a stock option grant covering 16,500 Common Shares at an exercise price of $67.74 on October 3, 2025. The option vests in 48 equal monthly installments beginning November 3, 2025 and carries an expiration date of October 3, 2035. The reporting person holds 16,500 derivative securities directly following the transaction.
On 09/17/2025 Samarth Kulkarni, Chief Executive Officer and a Director of CRISPR Therapeutics AG (CRSP), reported a transaction on Form 4 showing he donated 6,000 common shares to a donor-advised fund. The Form 4 shows 201,004 shares beneficially owned directly after the transaction and 85,622 shares indirectly held through the Kulkarni 2023 GRAT. The filing is signed on 09/19/2025 and notes the donation as the reason for the disposition; the reported price is $0.00, indicating a charitable transfer rather than a sale for proceeds.
Samarth Kulkarni, Chief Executive Officer and director of CRISPR Therapeutics AG (CRSP), had 25,000 restricted stock units vest on 08/16/2025, each converting to one common share. To satisfy tax withholding required by the company's RSU Settlement Policy, the reporting person sold 13,081 shares on 08/18/2025 at a price of $58.15 per share. After these transactions the reporting person directly beneficially owns 207,004 common shares and indirectly owns 85,622 common shares through the Kulkarni 2023 GRAT. The sale was described as mandated to cover tax withholding and not a discretionary trade.
CRISPR Therapeutics director Douglas A. Treco reported buying common shares of the company. On August 6, 2025, he made an open-market purchase of 20,000 common shares at a weighted average price of $57.03 per share. Following this transaction, he directly owns 22,000 common shares of CRISPR Therapeutics.